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Abstract  
Background/Purpose: Cirrhosis – clinically overt, advanced liver disease – is associated with 
an increased risk of hemorrhagic stroke and poor stroke outcomes. We sought to investigate 
whether subclinical liver disease, specifically liver fibrosis, is associated with clinical and 
radiological outcomes in patients with primary intracerebral hemorrhage. 
Methods: We performed a retrospective cohort study using data from the Virtual International 
Stroke Trials Archive-ICH. We included adult patients with primary ICH presenting within 6 
hours of symptom onset. We calculated three validated fibrosis indices—Aspartate 
aminotransferase Platelet Ratio Index (APRI), Fibrosis-4 (FIB-4) score, and Nonalcoholic Fatty 
Liver Disease Fibrosis Score (NFS)—and modeled them as continuous exposure variables. 
Primary outcomes were admission hematoma volume and hematoma expansion. Secondary 
outcomes were mortality, and the composite of major disability or death, at 90 days. We used 
linear and logistic regression models adjusted for previously established risk factors.  
Results: Among 432 patients with ICH, the mean APRI, FIB-4, and NFS values on admission 
reflected intermediate probabilities of fibrosis, while standard hepatic assays and coagulation 
parameters were largely normal. After adjusting for potential confounders, APRI was associated 
with hematoma volume (β, 0.20; 95% CI, 0.04-0.36), hematoma expansion (OR, 1.6; 95% CI, 
1.1-2.3), and mortality (OR, 1.8; 95% CI, 1.1-2.7). FIB-4 was also associated with hematoma 
volume (β, 0.27; 95% CI, 0.07-0.47), hematoma expansion (OR, 1.9; 95% CI, 1.2-3.0), and 
mortality (OR, 2.0; 95% CI, 1.1-3.6). NFS was not associated with any outcome. Indices were 
not associated with the composite of major disability or death.  
Conclusions: In patients with largely normal liver chemistries, two liver fibrosis indices were 
associated with admission hematoma volume, hematoma expansion, and mortality after ICH. 
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Introduction 
Liver cirrhosis is associated with an increased risk of stroke, particularly hemorrhagic stroke.1, 2 
Furthermore, we previously demonstrated that cirrhosis is associated with in-hospital mortality 
and unfavorable discharge disposition after intracerebral hemorrhage (ICH).3 While these data 
highlight a possible link between advanced liver disease and poor stroke outcomes, it is unclear 
if these findings also apply to subclinical liver disease.  
 
Liver fibrosis, an often clinically silent manifestation of chronic liver disease and a histological 
precursor to cirrhosis, is present in up to 9% of individuals without known liver disease.4-6 Liver 
fibrosis is a key predictor of cardiovascular mortality in patients with chronic liver disease7-9 and 
is also associated with ischemic stroke risk10 and cerebral microbleeds,11 but data are lacking 
regarding the implications of liver fibrosis for patients with ICH. We therefore investigated the 
association between subclinical liver disease, defined using liver fibrosis indices, and ICH 
outcomes using a large, international cohort of patients without overt liver disease enrolled in 
clinical trials. We hypothesized that serum-based indices of liver fibrosis are associated with 
larger baseline hematoma volume, greater hematoma expansion, and worse clinical outcomes in 
patients with ICH.  
 
Methods 
Data Source and Study Design 
We performed a retrospective cohort study using data from the Virtual International Stroke 
Trials Archive ICH (VISTA-ICH).12 The VISTA database (www.vistacollaboration.org) houses 
anonymized, individual patient-level data from completed trials. Trials are eligible for inclusion 
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in VISTA-ICH if they meet the following requirements: 1) documented entry criteria into a trial 
with a minimum of 50 randomized patients with ICH; 2) documented consent or waiver of 
consent from a local ethics board; 3) baseline assessment within 24 hours of ICH; 4) baseline 
assessment of neurologic deficit at the time of admission; 5) confirmation of ICH by cerebral 
imaging within 7 days; 6) outcome assessment between 1 and 6 months with a validated stroke 
scale; and 7) data validation through monitoring.13 The VISTA cohort used in this study 
consisted of only patients in the placebo arm of all trials and intervention arms of negative non-
surgical trials. Individual trials that contributed to the dataset used for this analysis were 
performed with institutional review board and/or regulatory approval. Individual trials obtained 
informed consent. Our analysis was approved by the Weill Cornell Medicine institutional review 
board. The data used in this analysis are restricted per the terms of VISTA-ICH’s data use 
agreement and therefore cannot be shared directly with other investigators. However, 
investigators can obtain access to these data by submitting a formal application to VISTA-ICH. 
 
Population 
We included only adult patients with primary ICH who presented within 6 hours of symptom 
onset. We excluded patients with missing data on liver chemistries, baseline imaging, or 
important clinical covariates such as ICH severity (Figure 1). All patients had follow-up 
computed tomography (CT) scan at 72 hours and 90-day modified Rankin Scale (mRS) 
assessments. In order to minimize the contribution of potential confounding by alcohol use and 
competing causes of liver test abnormalities, we excluded patients with self-reported alcohol use 
and use of select medications: valproic acid, amiodarone, methotrexate, and tamoxifen.14  
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Exposures 
We calculated three non-invasive liver fibrosis indices for each participant at the time of 
admission: the Aspartate aminotransferase-Platelet Ratio Index (APRI), the Fibrosis-4 (FIB-4) 
score, and the Nonalcoholic Fatty Liver Disease Fibrosis Score (NFS).15-17 These indices are 
calculated from demographic variables, medical comorbidities, and laboratory data (Figure 2). 
Most individuals with covert liver fibrosis, especially after excluding those with alcohol abuse, 
have non-alcoholic fatty liver disease as the underlying etiology of liver fibrosis.4 Liver imaging 
data are not available in VISTA-ICH; however all three indices have been validated to have good 
accuracy for the non-invasive detection of liver fibrosis in patients with non-alcoholic fatty liver 
disease, with receiver-operating-characteristic curve values ranging from 0.76 to 0.88.18 Studies 
have validated the predictive accuracy of the indices at different thresholds; thresholds reflective 
of a high probability of advanced fibrosis are APRI > 1, FIB-4 score > 3.25, and NFS > 0.676.18 
The NFS range includes negative values. These indices have also been validated in the setting of 
hepatitis B (FIB-4), hepatitis C (APRI, FIB-4), and alcoholic liver disease (FIB-4).19-22  
 
Demographics and ICH Characteristics  
Demographic and clinical data included age, sex, hypertension, diabetes mellitus, 
hyperlipidemia, atrial fibrillation, smoking, and use of antiplatelet and anticoagulant medication. 
Admission Glasgow Coma Scale (GCS) score, National Institutes of Health Stroke Scale 
(NIHSS) score, and systolic blood pressure were also obtained at pre-specified time points. 
Laboratory data obtained include platelet count, coagulation parameters (International 
Normalized Ratio and partial thromboplastin time), and several liver chemistries (alanine 
aminotransferase, aspartate aminotransferase, albumin, and total bilirubin). Baseline radiological 
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data were admission hematoma volume, location (lobar, deep, and infratentorial), and 
intraventricular hemorrhage (present vs. absent).  
 
Outcomes 
Our primary outcomes were admission hematoma volume and hematoma expansion. Our 
secondary outcomes were all-cause mortality at 90 days, and death or major disability at 90 days.  
Major disability was defined as a modified Rankin Scale (mRS) score of 4 or greater. Hematoma 
volumes were calculated using semi-automated planimetry by individual trial neuroradiologists. 
Hematoma expansion was defined as an increase in the absolute hematoma volume by either 
33% or > 6 mL at 72 hours compared to the admission acquisition.23  
 
Statistical Analyses 
Patient characteristics were described using standard descriptive statistics. Discrete variables are 
presented as counts (percentages [%]) and continuous variables as means (standard deviation 
[SD]) or medians (interquartile range [IQR]), as appropriate. Pearson Chi-squared test was used 
for categorical variables as appropriate; the Student’s t test or Wilcoxon rank sum test were used 
for continuous variables depending on the normality of distribution. Fibrosis indices were log-
transformed to minimize skewness and treated as continuous variables.  
 
We used multiple logistic regression models to assess the relationships between each fibrosis 
index and binary outcomes. We a priori selected known predictors of hematoma expansion and 
clinical outcomes as covariates, which were age, sex, hematoma location, presence of 
intraventricular hemorrhage, GCS score, anticoagulant use, and time from symptom onset to 
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baseline CT scan.24, 25 The models did not include admission hematoma volume since we 
expected it to be a mediator in the causal pathway given our hypothesis.  
 
We used multiple linear regression to model associations between fibrosis indices and admission 
hematoma volume, both of which were log-transformed. Covariates were age, sex, hematoma 
location, antiplatelet use, and International Normalized Ratio, since these have previously been 
shown to be independent predictors of baseline hematoma volume in a large cohort of ICH 
patients.26 Collinear covariates, defined by a variance inflation factor > 4, were subsequently 
identified and removed from the model. We also performed sensitivity analyses excluding 
patients with thrombocytopenia (defined as platelet count <150,000 per microliter). Statistical 
analyses were performed using Stata (version 14.0, College Station, TX). All analyses were two-
tailed with the threshold of statistical significance allowing for an alpha error of 0.05. 
 
Results 
Characteristics of Study Population  
The VISTA-ICH dataset consisted of 591 patients of whom 432 were eligible for our study 
(Figure 1). The mean age was 66 years (SD, 12). There were 30 patients (7%) taking 
anticoagulant medications, and 37 patients (9%) had thrombocytopenia. Standard liver chemistry 
tests and coagulation indices were generally in the normal range in the study sample; 12% had an 
aspartate aminotransferase > 40 IU/L, 11% had an alanine aminotransferase > 40 IU/L, and 29% 
had an INR > 1.4 (Table 1). Baseline characteristics were stratified by Fibrosis-4 score (quartile 
4 versus quartiles 1-3) to demonstrate how baseline characteristics may differ with fibrosis 
indices. Mean aspartate aminotransferase values and the proportion with thrombocytopenia were 
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greater among those with a FIB-4 score in the highest quartile (Table 1). The mean APRI, FIB-4, 
and NFS values were 0.4 (SD, 0.4), 1.9 (SD 1.4), and 0.3 (SD, 1.3), respectively; these means 
reflect intermediate or indeterminate probabilities of fibrosis. When validated thresholds were 
used, there were 32 patients (7%) with a high probability of fibrosis by the APRI, 41 patients 
(9%) by the FIB-4, and 142 patients (33%) by the NFS.  
 
Fibrosis Indices and Hematoma Admission Hematoma Volume  
The median admission hematoma volume was 16.1 mL (IQR, 8.1-29.6). Multiple linear 
regression models adjusted for age, sex, hematoma location, antiplatelet use, International 
Normalized Ratio, and time from symptom onset to baseline CT scan showed associations with 
hematoma volume for APRI (β, 0.20; 95% CI, 0.04-0.36) and FIB-4 (β, 0.27; 95% CI, 0.07-0.47) 
but not NFS (β, 0.03; 95% CI, -0.07-0.13) (Table 2).  
 
Fibrosis Indices and Hematoma Expansion  
One hundred and forty-five patients (34%) had hematoma expansion. Multiple logistic regression 
models adjusted for age, sex, admission GCS, hematoma location, intraventricular hemorrhage, 
anticoagulant use, and time from symptom onset to baseline CT scan showed associations with 
hematoma expansion for APRI (OR per each 10-fold increase, 1.6; 95% CI, 1.1-2.3) and FIB-4 
(OR per each 10-fold increase, 1.9; 95% CI, 1.2-3.0), but not for NFS (OR per each 10-fold 
increase, 1.2; 95% CI, 0.9-1.5) (Table 2).  
 
Fibrosis Indices and Clinical Outcomes 
At 90 days, there were 75 (17%) deaths, and 220 (51%) patients had a modified Rankin Scale 
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score of 4 or greater. Multiple logistic regression models adjusted for age, sex, hematoma 
location, intraventricular hemorrhage, admission GCS, and anticoagulant use showed 
associations with 90-day mortality for APRI (OR per each 10-fold increase, 1.8; 95% CI, 1.1-
2.7) and FIB-4 (OR per each 10-fold increase, 2.0; 95% CI, 1.1-3.6), but not for NFS (OR per 
each 10-fold increase, 1.2; 95% CI, 0.9-1.8) (Table 2). None of the indices were associated with 
the composite of major disability or death at 90 days. The direction and magnitude of effect were 
generally consistent with the primary analysis for all outcomes in post-hoc sex-stratified analyses 
(please see https://www.ahajournals.org/journal/str). 
 
Sensitivity Analyses 
In a sensitivity analysis excluding patients with thrombocytopenia (n=37, 9%), the APRI and 
FIB-4 fibrosis indices remained associated with admission hematoma volume and hematoma 
expansion (Table 3). While the direction of effect remained consistent with the primary analyses 
for the association between APRI and FIB-4 and all-cause mortality, the effect size and statistical 
significance were attenuated (Table 3). No associations were noted with the composite of 90-day 
death or major disability, and NFS was not associated with any outcomes of interest, consistent 
with the results of the primary analysis. 
 
Discussion 
In this international, multicenter cohort of patients with ICH, two serum-based liver fibrosis 
indices were independently associated with admission hematoma volume, hematoma expansion, 
and 90-day mortality, but not the composite of death or major disability. Notably, these 
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associations were observed in a population with standard liver chemistries generally in the 
normal range.  
 
To our knowledge, the association between validated liver fibrosis indices and ICH 
characteristics and outcomes has not been studied previously. Prior studies have inconclusively 
suggested that severe derangements in individual liver enzyme tests are associated with higher 
hematoma volumes and hematoma expansion.27-31 However, these studies evaluated individual, 
non-specific liver enzyme tests in populations with heavy alcohol use. In contrast, we present a 
novel association between validated liver fibrosis indices and admission hematoma volume and 
hematoma expansion. In this context, our study presents novel findings that liver fibrosis may 
reflect a propensity for increased bleeding as evidenced by higher admission ICH volumes and 
hematoma expansion, in the absence of obvious clinical manifestations or laboratory 
derangements otherwise typically expected with overt liver disease. This is consistent with the 
observation that standard liver chemistries are commonly normal in patients with chronic liver 
disease; transaminase levels are normal in up to 75% of individuals with imaging evidence of 
significant liver fibrosis.4, 32 Taken together, these data raise the possibility that subclinical liver 
fibrosis – liver fibrosis not consistently identifiable with standard liver chemistries – is 
associated with higher admission ICH volumes and hematoma expansion. Possible mechanisms 
may include subclinical coagulopathy, endothelial dysfunction, and vascular inflammation.33-36 
These mechanisms were described in patients with clinically diagnosed liver disease; whether 
these mechanisms can be implicated to explain our findings with regards to subclinical liver 
fibrosis is a hypothesis that requires testing in future studies. Further investigation with more 
direct measures of liver fibrosis, such as biopsy results or advanced imaging data, detailed liver-
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specific comorbidity data, and mechanistic data, is warranted to better understand the 
pathophysiology of our findings and better support any explicit causal inferences regarding liver 
fibrosis itself.  
 
Liver fibrosis indices were also associated with mortality in our study. Prior studies evaluating 
the relationship between liver disease and ICH outcomes have considered either isolated 
abnormalities in individual liver enzyme levels or included patients with clinically overt liver 
disease. One such study found that subclinical derangements in individual hepatic enzymes, such 
aspartate aminotransferase and alkaline phosphatase, were associated with worse clinical 
outcomes in ICH in univariable analysis, but these associations were not present after adjustment 
for confounders.37 Similarly, isolated hypoalbuminemia has been associated with increased 90-
day mortality in ICH.38 With regards to clinically overt liver disease, we have previously 
demonstrated using administrative claims data that patients with liver disease have less favorable 
hospital discharge disposition and greater in-hospital mortality compared to those without.3 
Additionally, among a small cohort of patients with known chronic liver disease primarily due to 
alcohol or viral hepatitis, liver cirrhosis was associated with greater in-hospital mortality in 
ICH.39 Our results build upon these data by demonstrating an association between liver fibrosis 
indices and 90-day mortality in ICH among individuals with largely normal standard liver 
chemistries and coagulation indices. Although increased hematoma growth offers one possible 
explanation, increased susceptibility to infections and liver-related complications, as shown in 
other studies, may provide alternative reasons for higher mortality after ICH.38-40 The 
discrepancy between 90-day mortality and the composite of 90-day death or major disability in 
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our study suggests that non-neurological or otherwise non-disabling complications such as those 
directly related to liver disease, may account for our findings.   
 
Strengths of our study include the use of a well-adjudicated ICH cohort with strict inclusion 
criteria, pre-specified time points for radiological measurements, the availability of standardized 
outcome assessments, and the analysis of relatively homogenous clinical trial populations with 
exclusion of patients with overt liver disease and coagulopathy. Our results should be interpreted 
while considering an important caveat: our study investigated the associations between serum-
based liver fibrosis indices and ICH outcomes. These indices are surrogate markers and 
screening tools for liver fibrosis, and we did not have advanced liver imaging or liver biopsy data 
to corroborate the ascertainment of liver fibrosis in our study population. While our use of liver 
fibrosis indices is consistent with other efforts to understand the impact of liver fibrosis on other 
disease processes,41, 42 our results should be interpreted while considering the performance of 
these liver fibrosis indices. Though the prevalence of fibrosis by the APRI and FIB-4 in our 
cohort was reassuringly consistent with population-based estimates (5-9%),4-6 our data suggest 
that the NFS performed poorly in the VISTA-ICH cohort. Specifically, the proportion of patients 
with an NFS above its high-probability cut-off in our cohort was 33%. This suggests that, 
compared to the APRI and FIB-4, the NFS was non-specific in our sample. The NFS formula 
includes body mass index, diabetes, and impaired fasting glucose, which reflect this score’s 
validation primarily for the detection of advanced fibrosis among patients with non-alcoholic 
fatty liver disease. In contrast, the simpler APRI and FIB-4 have been validated in more liver 
diseases19-22 and may be more appropriate for the general population, in which liver diseases may 
occur concurrently. Additionally, some components of the NFS, such as the body mass index, 
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may in fact have a paradoxically protective role after ICH.43, 44 These factors may account for 
discrepancies in associations across liver fibrosis indices.  
 
Our study has additional noteworthy limitations. First, inclusion of patients with low ICH 
severity who were enrolled in clinical trials may limit generalizability of our results. Second, our 
study population had a high mean body mass index; the extent to which liver fibrosis itself is 
responsible for our findings, as opposed to being an epiphenomenon related to obesity, requires 
further investigation. Third, viral hepatitis serologies were unavailable and self-reported alcohol 
use may have been imprecise; however, given that most clinical trials exclude patients with 
advanced liver disease or known alcohol abuse, we believe our study had few such patients. 
Some liver fibrosis indices have also been validated in patients with viral hepatitis and alcohol 
use.19-22  
 
Conclusions 
Among patients with ICH, two liver fibrosis indices were associated with admission hematoma 
volume, hematoma expansion, and 90-day mortality despite largely normal standard liver 
chemistries and coagulation parameters. Further study to examine the impact of subclinical liver 
disease on ICH outcomes is warranted. Such work may reveal novel targets for hemostasis and 
help identify patients at risk of hematoma expansion and poor outcomes who may benefit from 
targeted hemostatic therapies.  
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Figure Legends 
Figure 1. Patient flow diagram.   
Caption: Patients with missing laboratory data, known overt liver disease, alcohol use, and those 
using potentially hepatotoxic medications were excluded.  
 
Figure 2. Formulas for liver fibrosis indices. 
Caption: Fibrosis indices were the aspartate aminotransferase – platelet ratio index (APRI), 
Fibrosis-4 score (FIB-4), and nonalcoholic fatty liver disease – fibrosis score (NFS).  
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Table 1. Characteristics of Patients with Intracerebral Hemorrhage, Stratified by Fibrosis-4 Score 
Quartiles  
Characteristic*  
Study Sample 
(N=432) 
FIB-4 Score 
Quartile 4 
(N=108) 
FIB-4 Score 
Quartiles 1-3 
(N=324) 
Patient Characteristics     
   Age, mean (SD), years 65.5 (11.9) 73.6 (10.6) 62.8 (11.0) 
   Female sex 147 (34) 33 (31) 114 (35) 
   Race    
      White 357 (83) 97 (91) 260 (83) 
      Black 19 (4) 2 (2) 17 (5) 
      Other 46 (11) 8 (8) 38 (12) 
   Hypertension 350 (81) 86 (80) 264 (82) 
   Hyperlipidemia 69 (16) 15 (14) 54 (17) 
   Diabetes mellitus 78 (18) 14 (13) 64 (20) 
   Atrial fibrillation 37 (9) 19 (18) 18 (6) 
   Anticoagulant use 30 (7) 11 (11) 19 (6) 
   Antiplatelet use 93 (22) 35 (32) 58 (18) 
   Body mass index, mean (SD), kg/m2 27.4 (5.7) 30.3 (6.1) 27.4 (5.7) 
Admission Laboratory Data    
   Platelet count†, x103 per microliter  214 (179-258) 166 (144-194) 232 (198-272) 
   International Normalized Ratio† 1.0 (0.9-1.1) 1.0 (0.9-1.2) 1.0 (0.9-1.1) 
   International Normalized Ratio > 1.4 124 (29) 35 (32) 89 (27) 
   aPTT†, seconds 24.6 (21.5-29.2) 25.2(19.3-31.1) 24.6 (21.8-28.8) 
   AST†, units/liter 23 (19-29) 30 (23-51) 22 (18-26) 
   AST > 40 units/liter 51 (12) 34 (31) 17 (5) 
   ALT†, units/liter 20 (15-29) 20 (14-34) 20 (15-28) 
   ALT > 40 units/liter 46 (11) 22 (23) 24 (7) 
   Albumin†, gram/dL 4.1 (3.9-4.3) 4.1 (3.8-4.2) 4.1 (3.9-4.4) 
   Total bilirubin†, milligram/dL 0.5 (0.7) 0.6 (0.4-0.8) 0.4 (0.3-0.5) 
   Thrombocytopenia (<150,000/µL) 37 (8.6) 32 (29.6) 5 (1.5) 
Admission ICH Data    
   Glasgow Coma Scale† 15 (13-15) 14 (14-15) 15 (13-15) 
   National Institutes of Health Stroke Scale† 13 (9-17) 14 (10-18) 13 (9-17) 
   Time to admission CT scan†, hours 3.3 (1.3-5.5) 3.4 (1.4-5.0) 3.2 (1.3-5.6) 
   Hematoma volume at admission†, mL 16.1 (8.1-29.6) 21.1 (8.9-35.3) 14.9 (7.9-27.2) 
   Intraventricular hemorrhage 138 (32) 44 (41) 94 (29) 
   Hematoma location     
      Lobar  90 (21) 28 (26) 62 (19) 
      Deep 333 (77) 79 (73) 254 (78) 
      Infratentorial  9 (2) 1 (1) 8 (3) 
72-hour ICH Imaging Data    
   Hematoma volume at 72 hours†, mL 16.9 (8.1-33.8) 25.3 (9.9-43.2) 16.6 (8.1-31.5) 
   Time to 72-hour CT scan†, hours 69.9 (64.1-77.1) 70.5 (65.3-76.4) 69.6 (64.0-78.2) 
Abbreviations; SD, standard deviation; aPPT, activated partial thromboplastin time; AST, aspartate aminotransferase; ALT, 
alanine aminotransferase; dl, deciliter; mL, milliliters; µL, microliter. 
* Data reported as n (%) unless otherwise specified. †Data reported as median (interquartile range). 
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Table 2. Associations between Liver Fibrosis Indices and Admission Hematoma Volume, Hematoma Expansion, 
and Outcomes after ICH 
Outcome 
APRI* FIB-4* NFS* 
OR (95% CI) p value  OR (95% CI) p value  OR (95% CI) p value  
Hematoma expansion 1.6 (1.1-2.3) 0.01 1.9 (1.2-3.0) 0.01 1.2 (0.9-1.5)  0.22 
All-cause mortality 1.8 (1.1-2.7) 0.01 2.0 (1.1-3.6) 0.02 1.2 (0.9-1.8)  0.22 
Death or major disability 1.3 (0.9-1.8) 0.19 1.3 (0.8-2.1) 0.31 0.9 (0.8-1.2)  0.71 
 
 Beta (SE) p value Beta (SE) p value Beta (SE) p value 
Admission hematoma 
volume*,† 
0.20 (0.08) 0.01 0.27 (0.11) 0.01 0.03 (0.05) 0.53 
Abbreviations: mRS, modified Rankin Scale; APRI, aspartate aminotransferase-platelet ratio index; FIB-4, fibrosis-
4 score; NFS, Nonalcoholic Fatty Liver Disease Fibrosis score, SE, Standard Error.  
* Logarithmic transformation was performed to minimize skewness. 
†Linear regression was used. 
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Table 3. Associations between Liver Fibrosis Indices and Admission Hematoma Volume, Hematoma Expansion, 
and Outcomes after ICH after Excluding Patients with Thrombocytopenia 
Outcome 
APRI* FIB-4* NFS* 
OR (95% CI) p value  OR (95% CI) p value  OR (95% CI) p value  
Hematoma expansion 1.6 (1.1-2.3) 0.02 1.8 (1.1-2.9) 0.02 1.1 (0.9-1.4) 0.36 
All-cause mortality 1.6 (0.9-2.5) 0.08 1.6 (0.8- 3.1) 0.15 1.1 (0.8-1.6) 0.44 
Death or major disability 1.2 (0.8-1.8) 0.29 1.2 (0.7-2.0) 0.49 0.9 (0.8-1.3) 0.98 
 
 Beta (SE) p value Beta (SE) p value Beta (SE) p value 
Admission hematoma 
volume† 
0.3 (0.1) 0.003 0.4 (0.1) 0.002 0.06 (0.05) 0.28 
Abbreviations: mRS, modified Rankin Scale; APRI, aspartate aminotransferase-platelet ratio index; FIB-4, fibrosis-
4 score; NFS, Nonalcoholic Fatty Liver Disease Fibrosis score, SE, Standard Error.  
* Logarithmic transformation was performed to minimize skewness. 
† Linear regression was used. 
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